September 20, 2016 7:15am
… And the other heading to the exit door…
Leaving investors holding a bag of what?
I answer one question; in which company should investors put, keep and commit their money!
Where is “our” universe going today? Astute investors subscribe, you should too!
I say what others won't, so you can do what others can't!
How does the old saying go? It's easier to ask for forgiveness than ask for permission. Maybe it's the other way around. Whatever the case, to the extent I need to, I'm NOT going to ask for forgiveness for what I say – someone NEEDS to speak up and out!
Indexes and ETFs: IWM (+0.40%) and is UP while the IBB, XBI and the XLV are NOT indicating
Companies in my headlights: BUY – AGTC,
SELL – AST and KITE
Dow futures are UP +0.32% and NASDAQ futures are UP +0.34%
U.S. stock-index futures gained on Tuesday as traders awaited the start of the U.S. Federal Reserve's two-day meeting.
European stocks reversed early losses to trade higher as global investors awaited the outcomes of separate policy meetings of the U.S. Federal Reserve and Bank of Japan.
Asia markets were mixed, with traders likely taking to the sidelines to await Wednesday's closely watched monetary policy decisions due in the U.S. and Japan.
Data docket: U.S. housing starts and building permits data for August as well as oil prices
The stem, cell, gene and regenerative therapy (SCG&RT) sector closed NEGATIVE on Monday, POSITIVE on Friday, Thursday and Wednesday and NEGATIVE last Tuesday.
The SCG&RT sector’s record after the last 5 days (of 43 covered companies):
- Monday closed NEGATIVE with 22 decliners, 16 advancers and 5 flats;
- Friday closed POSITIVE with 18 decliners, 24 advancers and 1 flat;
- Thursday closed POSITIVE with 10 decliners, 29 advancers and 4 flats;
- Wednesday closed POSITIVE with 13 decliners, 26 advancers and 4 flats;
- Last Tuesday closed NEGATIVE with 34 decliners, 5 advancers and 4 flats;
Remembering Monday’s closing post, “What expectations have we as investors to look forward to? Volume is still low, volatility floats with momentum and that’s low … which also says … to me – caution about the next few weeks. The start of the week doesn’t provide us with any insight, since we know to expect the unexpected.”
- However, I did state Monday would be a down day based on the “pattern” of the advance/decline lines (A/DL) and negative versus positive closings over the past eleven sessions.
I don't worry anymore about what’s to going to happen on Monday but, it’s Tuesday that is always in the air.
- “The stem, cell, gene and regenerative therapy (SCGT&RT) sector was neutral at the opening bell, dipped negative at the mid-day with the sector closing negative.”
Trading has been driving the stock-market bus …
You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades?
Watch list:
- The iShares Nasdaq Biotechnology (IBB) closed Monday down -0.04% and is NOT indicating in Tuesday’s pre-market;
- The SPDR S&P Biotech ETF (XBI) closed Monday up +1.82% and is NOT indicating in Tuesday pre-market;
- The Health Care Select Sector SPDR ETF (XLV) closed down -0.36% Monday and is NOT indicating in Tuesday’s pre-market;
- The iShares Russell 2000 (IWM) closed up +0.66% on Monday and is UP +0.40% in Tuesday’s pre-market.
Companies in my headlights:
Applied Genetic Technologies (AGTC) closed DOWN -$0.34 to $8.59. Let me make it simple, AGTC’s stock is worth $9.87 in cash per share and has NO debt – BUY;
Asterias Biotherapeutics (NYSEMKT: AST) closed UP +$0.47 to $4.42. September has been good for AST, having started at $2.82 and some good news but, how long does the “shine” last? – SELL;
Kite Pharma (KITE) closed DOWN -$1.62 to $56.01. The dice are hot but the floor is cold – SELL;
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
